US-based biotech firm Intrexon has partnered with Sanofi Chimie to develop an effective production process for a specific family of its marketed active pharmaceutical ingredients (APIs).

The companies have signed an exclusive channel collaboration (ECC) to enhance and optimise APIs production process by using its current manufacturing operations in France.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As part of the deal, Intrexon will use Sanofi’s advanced computational biology and bioinformatics to identify the efficient biological pathways to produce marketed APIs.

"We are confident that our synthetic biology expertise and robust technology platforms will drive development of Sanofi’s next-generation strain in a commercially feasible way that also produces the highest possible yields."

The industrial product division facilities of Intrexon, located in Hungary and California, will develop and synthesise new components to drive optimal output from constructed cell lines.

Intrexon chairman and CEO Randal Kirk said: "We are excited to partner with Sanofi to improve existing fermentation processes, providing a competitive advantage in marketed APIs production.

"We are confident that our synthetic biology expertise and robust technology platforms will drive development of Sanofi’s next-generation strain in a commercially feasible way that also produces the highest possible yields."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Intrexon noted that collaboration will leverage its proprietary technology suite, as well as Sanofi’s expertise and innovation in yeast metabolism and industrial chemistry to increase overall yield.

Intrexon plans to provide its new BeyondBio platform to Sanofi for accessing extensive library of characterised genetic components, which facilitates customised gene design and high-throughput modular DNA assembly.

The company, through its UltraVector platform and suite of technologies, helps its partners in the industrial-scale design and development of complex biological systems.